The promise of rituximab in connective tissue disease-associated interstitial lung disease.
作者信息
Wong M L
机构信息
Division of Pulmonology, Department of Medicine, Chris Hani Baragwanath Academic Hospital and School of Clinical Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
出版信息
Afr J Thorac Crit Care Med. 2024 Oct 14;30(3):e2683. doi: 10.7196/AJTCCM.2024.v30i3.2683. eCollection 2024.
Abstract
摘要
相似文献
1
The promise of rituximab in connective tissue disease-associated interstitial lung disease.利妥昔单抗在结缔组织病相关间质性肺病中的应用前景。
Afr J Thorac Crit Care Med. 2024 Oct 14;30(3):e2683. doi: 10.7196/AJTCCM.2024.v30i3.2683. eCollection 2024.
2
Rituximab in connective tissue disease-associated interstitial lung disease.利妥昔单抗治疗结缔组织病相关间质性肺疾病。
Clin Rheumatol. 2019 Jul;38(7):2001-2009. doi: 10.1007/s10067-019-04557-7. Epub 2019 Apr 23.
3
Rituximab versus cyclophosphamide for the treatment of connective tissue disease-associated interstitial lung disease (RECITAL): study protocol for a randomised controlled trial.利妥昔单抗与环磷酰胺治疗结缔组织病相关间质性肺病（RECITAL）：一项随机对照试验的研究方案
Trials. 2017 Jun 15;18(1):275. doi: 10.1186/s13063-017-2016-2.
4
Safety and efficacy of rituximab in connective tissue disease-associated interstitial lung disease: A systematic review and meta-analysis.利妥昔单抗治疗结缔组织病相关间质性肺疾病的安全性和有效性：系统评价和荟萃分析。
Int Immunopharmacol. 2021 Jun;95:107524. doi: 10.1016/j.intimp.2021.107524. Epub 2021 Mar 12.
5
Rituximab effect in severe progressive connective tissue disease-related lung disease: preliminary data.利妥昔单抗在严重进行性结缔组织病相关肺部疾病中的疗效：初步数据。
Rheumatol Int. 2020 May;40(5):719-726. doi: 10.1007/s00296-020-04545-0. Epub 2020 Mar 10.
6
Rituximab for the treatment of acute exacerbation of interstitial lung disease associated with connective tissue disease.利妥昔单抗治疗与结缔组织病相关的间质性肺疾病急性加重。
RMD Open. 2023 Sep;9(3). doi: 10.1136/rmdopen-2023-003479.
7
Effects of cyclophosphamide and rituximab in patients with connective tissue diseases with severe interstitial lung disease.环磷酰胺和利妥昔单抗治疗结缔组织病相关严重间质性肺疾病的效果。
Clin Exp Rheumatol. 2022 Mar;40(3):483-488. doi: 10.55563/clinexprheumatol/o5t1f7. Epub 2021 Feb 25.
8
Rituximab in autoimmune connective tissue disease-associated interstitial lung disease.利妥昔单抗在自身免疫性结缔组织病相关间质性肺疾病中的应用
Rheumatology (Oxford). 2016 Jul;55(7):1318-24. doi: 10.1093/rheumatology/kew195. Epub 2016 Apr 8.
9
Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial.利妥昔单抗与静脉注射环磷酰胺治疗英国结缔组织病相关间质性肺病患者（RECITAL）：一项双盲、双模拟、随机、对照、2b 期试验。
Lancet Respir Med. 2023 Jan;11(1):45-54. doi: 10.1016/S2213-2600(22)00359-9. Epub 2022 Nov 11.
10
Comment on: rituximab in autoimmune connective tissue disease-associated interstitial lung disease.关于《利妥昔单抗治疗自身免疫性结缔组织病相关间质性肺疾病》的评论
Rheumatology (Oxford). 2016 Dec;55(12):2279-2280. doi: 10.1093/rheumatology/kew311. Epub 2016 Aug 21.
本文引用的文献
1
In vitro co-culture studies and the crucial role of fibroblast-immune cell crosstalk in IPF pathogenesis.体外共培养研究和成纤维细胞-免疫细胞相互作用在特发性肺纤维化发病机制中的关键作用。
Respir Res. 2023 Nov 27;24(1):298. doi: 10.1186/s12931-023-02608-x.
2
Better Safe than Sorry: Rheumatoid Arthritis, Interstitial Lung Disease, and Medication-A Narrative Review.宁求稳妥，不抱遗憾：类风湿关节炎、间质性肺疾病与药物——一篇叙述性综述
Biomedicines. 2023 Jun 19;11(6):1755. doi: 10.3390/biomedicines11061755.
3
Rituximab and mycophenolate mofetil combination in patients with interstitial lung disease (EVER-ILD): a double-blind, randomised, placebo-controlled trial.利妥昔单抗和霉酚酸酯联合治疗间质性肺病患者（EVER-ILD）：一项双盲、随机、安慰剂对照试验。
Eur Respir J. 2023 Jun 8;61(6). doi: 10.1183/13993003.02071-2022. Print 2023 Jun.
4
[89Zr]-immuno-PET prediction of response to rituximab treatment in patients with therapy refractory interstitial pneumonitis: a phase 2 trial.[89Zr]-免疫 PET 预测利妥昔单抗治疗难治性间质性肺炎患者的反应：一项 2 期试验。
Eur J Nucl Med Mol Imaging. 2023 Jun;50(7):1929-1939. doi: 10.1007/s00259-023-06143-1. Epub 2023 Feb 24.
5
Hypogammaglobulinemia, late-onset neutropenia, and infections following rituximab.利妥昔单抗治疗后低丙种球蛋白血症、迟发性中性粒细胞减少和感染。
Ann Allergy Asthma Immunol. 2023 Jun;130(6):699-712. doi: 10.1016/j.anai.2023.01.018. Epub 2023 Jan 24.
6
Rituximab for connective tissue disease-associated interstitial lung disease: A systematic review and meta-analysis.利妥昔单抗治疗结缔组织病相关间质性肺病：一项系统评价和荟萃分析。
Int J Rheum Dis. 2023 Feb;26(2):225-235. doi: 10.1111/1756-185X.14495. Epub 2022 Nov 15.
7
Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial.利妥昔单抗与静脉注射环磷酰胺治疗英国结缔组织病相关间质性肺病患者（RECITAL）：一项双盲、双模拟、随机、对照、2b 期试验。
Lancet Respir Med. 2023 Jan;11(1):45-54. doi: 10.1016/S2213-2600(22)00359-9. Epub 2022 Nov 11.
8
COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study.接受利妥昔单抗治疗的炎症性风湿和肌肉骨骼疾病患者的COVID-19结局：一项队列研究。
Lancet Rheumatol. 2021 Jun;3(6):e419-e426. doi: 10.1016/S2665-9913(21)00059-X. Epub 2021 Mar 25.
9
Antifibrotics Modify B-Cell-induced Fibroblast Migration and Activation in Patients with Idiopathic Pulmonary Fibrosis.抗纤维化药物可改变特发性肺纤维化患者中 B 细胞诱导的成纤维细胞迁移和激活。
Am J Respir Cell Mol Biol. 2021 Jun;64(6):722-733. doi: 10.1165/rcmb.2020-0387OC.
10
Efficacy and safety of rituximab in the treatment of connective tissue disease-related interstitial lung disease.利妥昔单抗治疗结缔组织病相关间质性肺疾病的疗效与安全性。
Drugs Context. 2021 Jan 15;10. doi: 10.7573/dic.2020-8-7. eCollection 2021.
Zotero 插件